This report on Alzheimer’s disease represents selections from the larger market
research study on neurotherapeutic drugs published by Kalorama Information in
August 2002. The full study looked at the entire range of non-psychiatric neurological
diseases and their treatments in the top seven world health markets. Here we present
those parts of that study that are germane to Alzheimer’s disease.
In addition to the relevant selections, which are indicated on the Table of Contents
and List of Exhibits in bold face with page numbers, we have also included the
following in this report:
The complete Executive Summary from the full study;
Discussion of promising cutting-edge technologies and treatments with
potentially broad application not limited to Alzheimer’s;
Top-level market numbers on the total worldwide market for
The Conclusions and Strategic Implications from the full study;
Appendix A: Glossary of Terms; and
Appendix B: Company Directory
Alzheimer’s: Selections from "The World Market for Neurotherapeutic Drugs"
In the summer of 2002, Kalorama Information released a major study on non-psychiatric neurotherapeutic drug markets. At almost 500 pages, the resultant report covered a broad range of neurological agents comprehensively and in depth; however, the breadth and authority of the results proved to be more information than some marketers needed. Smaller biopharmaceutical concerns—some of the real drivers of this market—are more focused on individual neurological disorders such as multiple sclerosis, Alzheimer’s disease, or neurological cancers, rather than the broad therapeutic category as a whole.
Therefore, Kalorama is now offering selections from the neurotherapeutics study, covering each of these topics in turn, while at the same time providing selected overall findings in other disease areas to allow for comparison and context. The selections provide the study’s full results in the specific area and the general context and strategic implications from the full study, all at a fraction of the cost.
Among the selections, you’ll find:
I. Executive Summary (15 pages) —Included in this selection is the complete executive summary from the full neurotherapeutics report, providing you with an overview of the entire neurotherapeutics market and top-level numbers on such neurological diseases as peripheral neuropathy, Parkinson’s disease, and Alzheimer’s disease, among others for the top seven world markets. The executive summary outlines the context of the entire neurology market and how MS therapeutics fit in.
II. Introduction (2 pages) —Selection includes the overview of Alzheimer’s disease, including prevalence estimates.
III. Treatment (10 pages) —This selection reviews current treatment protocols and the agents used in Alzheimer’s, including antipsychotics, anxiolytics, antidepressants, and
IV. Progress and Promise in Therapeutic Development (31 pages) —Because progress on other neurotherapeutic fronts can have significant impact on Alzheimer therapeutics, information about all of the developments in neurogenomics and neural implants that the full study covered are included in this selection. Information specific to Alzheimer’s disease includes Table 4-2: Active Clinical Trials Involving Alzheimer’s Disease.
V. World Market Analysis (28 pages, including 10 tables and 4 figures) —Selection provides complete market projections and growth rates for Alzheimer’s therapeutics in each of the top world markets. Growth rates for Alzheimer’s markets and those of other major neurological diseases are included, along with total world numbers for comparison.
VI. Company Profiles (104 pages) —Profiles of the following companies are included:
Boston Life Sciences, Inc.
Centaur Pharmaceuticals, Inc.
Cephalon, Inc. Cortex Pharmaceuticals, Inc.
Elan Corporation plc
Guilford Pharmaceuticals Inc.
NPS Pharmaceuticals, Inc.
Neurobiological Technologies, Inc.
Neurocrine BioSciences, Inc.
Shire Pharmaceuticals Group plc
Stem Cells Inc.
Titan Pharmaceuticals, Inc.
VII. Conclusions and Strategic Implications (9 pages) —This selection represents all of the analyst’s conclusions from the neurotherapeutics study as a whole, spelling out seven main conclusions and what they mean for developers and marketers of neurotherapeutic agents.